Pembrolizumab-chemotherapy for advanced oesophageal cancer

被引：0
|
作者：
Gil, Ziv [1 ,2 ]
Billan, Salem [3 ]
机构：
[1] Israel Inst Technol, Head & Neck Surg Unit, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
[2] Israel Inst Technol, Head & Neck Ctr, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
[3] Israel Inst Technol, Dept Oncol & Radiat, Head & Neck Ctr, Rambam Hlth Care Campus, IL-31096 Haifa, Israel
来源：
LANCET | 2021年 / 398卷 / 10302期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：726 / 727
页数：2
相关论文
共 50 条
  • [1] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
    Wu, Meiyu
    Qin, Shuxia
    Wang, Liting
    Tan, Chongqing
    Peng, Ye
    Zeng, Xiaohui
    Luo, Xia
    Yi, Lidan
    Wan, Xiaomin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Pembrolizumab plus Chemotherapy as First-Line Treatment in advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGE, 2022, 28 (05): : 436 - 437
  • [3] Provision of Palliative Combined Pembrolizumab-Chemotherapy in Head and Neck Cancer in England: Time for a Review of the Evidence
    Kelly, C.
    Barnett, G.
    Iqbal, M. S.
    CLINICAL ONCOLOGY, 2024, 36 (09) : 534 - 536
  • [4] Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
    Eskander, Ramez N.
    Sill, Michael W.
    Beffa, Lindsey
    Moore, Richard G.
    Hope, Joanie M.
    Musa, Fernanda B.
    Mannel, Robert
    Shahin, Mark S.
    Cantuaria, Guilherme H.
    Girda, Eugenia
    Mathews, Cara
    Kavecansky, Juraj
    Leath, Charles A.
    Gien, Lilian T.
    Hinchcliff, Emily M.
    Lele, Shashikant B.
    Landrum, Lisa M.
    Backes, Floor
    O'Cearbhaill, Roisin E.
    Al Baghdadi, Tareq
    Hill, Emily K.
    Thaker, Premal H.
    John, Veena S.
    Welch, Stephen
    Fader, Amanda N.
    Powell, Matthew A.
    Aghajanian, Carol
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (07) : 406 - 407
  • [5] Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
    Eskander, Ramez N.
    Sill, Michael W.
    Beffa, Lindsey
    Moore, Richard G.
    Hope, Joanie M.
    Musa, Fernanda B.
    Mannel, Robert
    Shahin, Mark S.
    Cantuaria, Guilherme H.
    Girda, Eugenia
    Mathews, Cara
    Kavecansky, Juraj
    Leath III, Charles A.
    Gien, Lilian T.
    Hinchcliff, Emily M.
    Lele, Shashikant B.
    Landrum, Lisa M.
    Backes, Floor
    O'Cearbhaill, Roisin E.
    Al Baghdadi, Tareq
    Hill, Emily K.
    Thaker, Premal H.
    John, Veena S.
    Welch, Stephen
    Fader, Amanda N.
    Powell, Matthew A.
    Aghajanian, Carol
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (23): : 2159 - 2170
  • [6] Pembrolizumab plus chemotherapy for advanced gastric cancer
    Rha, Sun Young
    Bordia, Sonal
    LANCET ONCOLOGY, 2024, 25 (02): : e52 - e52
  • [7] Pembrolizumab and Chemotherapy Combination as a First-line Treatment in Patients with advanced Oesophageal Cancer (KEYNOTE-590)
    Hartmann, Milan
    Zander, Thomas
    Alakus, Hakan
    ONKOLOGIE, 2022, 28 (05): : 436 - 437
  • [8] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
    Descourt, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
  • [9] Pembrolizumab versus Chemotherapy for Patients with advanced Esophageal Cancer
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (04): : 304 - 304
  • [10] Induction chemotherapy followed by surgery for advanced oesophageal cancer
    Toxopeus, E. L. A.
    Talman, S.
    van der Gaast, A.
    Spaander, V. M. C. W.
    van Rij, C. M.
    Krak, N. C.
    Biermann, K.
    Tilanus, H. W.
    Mathijssen, R. H. J.
    van Lanschot, J. J. B.
    Wijnhoven, B. P. L.
    EJSO, 2015, 41 (03): : 323 - 332
12345